Osteosarcoma

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Ritter, J ^a   Bielack, S S ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b OLGAHOSPITAL   (Germany)

Author keywords

Follow up; Limb salvage; Multidisciplinary treatment; Osteosarcoma; Preoperative (neoadjuvant) chemotherapy; Surgical techniques

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; IMMUNOMODULATING AGENT; METHOTREXATE; MURAMYL TRIPEPTIDE PHOSPHATIDYL ETHANOLAMINE; NARCOTIC ANALGESIC AGENT; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE RADIOGRAPHY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PAIN; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; EVENT FREE SURVIVAL; FOLLOW UP; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE;

BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; RECURRENCE;

EID: 78649343858     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq276     Document Type: Conference Paper

References (50)

1. Fletcher CDM, Unni KK. Pathology and genetics of tumours of soft tissue and bone. In Mertens F (ed): World Health Organization Classification of Tumours. Lyon, France: IARC Press 2002.
2. Sobin LH, Wittekind C. UICC-TNM Classificaton of Malignant Tumors. New York: Wiley 2002.
3. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
4. Stiller CA, Bielack SS, Jundt G et al. Bone tumours in European children and adolescents, 1978-1997. Report form the Automated Childhood Cancer Infromation System project. Eur J Cancer 2006; 42: 2124-2135.
5. Stiller CA, Craft AW, Corazziari I. Survival of children with bone sarcoma in Europe since 1978: results form the EUROCARE study. Eur J Cancer 2001; 37: 760-766.
6. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-752.
7. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1.702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
8. Bielack S, Jürgens H, Jundt G et al. Osteosarcoma: the COSS experience. Cancer Treat Res 2009; 152: 289-308.
9. Ozaki T, Flege S, Liljenquist U et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer 2002; 94: 1069-1077.
10. Meyer JS, Nadel HR, Marina N et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51: 163-170.
11. Wuisman P, Enneking WF. Prognosis of patients who have osteosarcoma with skip metastasis. J Bone Joint Surg 1990; 72A: 60-68.
12. Kager L, Zoubek A, Kastner U et al. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006; 24: 1535-1541.
13. Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177.
14. Winkler K, Beron G, Kotz R et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-624.
15. Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-1606.
16. Eilber F, Giuliano A, Eckardt J et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5: 21-6.
17. Enneking WF, Soanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153: 106-120.
18. Gosheger G, Gebert C, Ahrens H et al. Endoprosthetic reconstrction in 250 patients with sarcoma. Clin Orthop 2006; 450: 164-171.
19. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol 2005; 6: 85-92.
20. Kotz RI, Windhager R, Dominkus M et al. A self-extending pediatric leg implant. Nature 2000; 406: 143-144.
21. Hillmann A, Hoffmann C, Gosheger G et al. Malignant tumor of the distal part of the femur or the proximal part of the tibia: endoprosthetic replacement or rotationsplasty. Functional outcome and quality-of-life measurements. J Bone Joint Surg Am 1999; 81: 462-468.
22. Ozaki T, Flege S, Kevric M et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2003; 21: 334-341.
23. Tomita K, Kawahara N, Murakami H et al. Total en bloc spondylectomy for spinal tumors: improvement of the technique and its associated basic background. J Orthop Sci 2006; 11: 3-12.
24. Hoffmann C, Gosheger G, Gebert C et al. Functional results and quality of life after treatment of pelvic sarcomas involving the acetabulum. J Bone Joint Surg Am 2006; 88: 575-582.
25. Schwarz R, Bruland O, Cassoni A et al. The role of radiotherapy in osteosarcoma. Cancer Treat Res 2009; 152: 147-165.
26. Franzius C, Bielack S, Flege S et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 2001; 40: 215-220.
27. Franzius C, Schuck A, Bielack SS. High-dose Samarium-153 ethylene diamine tetramethylene phophonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20: 1953-1954.
28. Cortes EP, Holland JF, Wang JJ et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974; 291: 998-1000.
29. Ochs JJ, Freeman AI, Douglass HO et al. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978; 62: 239-245.
30. Jaffe N, Paed D, Farber S et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973; 31: 1367-1373.
31. Harris MB, Cantor AB, Goorin AM et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995; 24: 87-92.
32. Goorin AM, Schwartzentruber DJ, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21: 1574-1580.
33. Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologie 1983; 4: 135-141.
34. Sauerbrey A, Bielack S, Kempf-Bielack B et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCI) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transpl 2001; 27: 933-937.
35. Strander H, Bauer HC, Brosjo O et al. Long-term adjuvant interferon treatment of human osteosarcoma: a pilot study. Acta Oncol 1995; 34: 877-880.
36. Marina N, Bielack S, Whelan J et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009; 152: 339-354.
37. Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival: a report from the Childreńs Oncology Group. J Clin Oncol 2008; 26: 633-638.
38. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results (letter). J Clin Oncol 2008; 26: 3103-3104; author reply 3104-3105.
39. Bielack S, Marina N, Ferrari S et al. Osteosarcoma: the same old drugs or more? (letter). J Clin Oncol 2008; 26: 3102-3103; author reply 3104-3105.
40. Alvarez O, Freeman A, Bedros A et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995; 17: 145-150.
41. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
42. Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
43. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term suvival. J Clin Oncol 2003; 21: 710-715.
44. Kempf-Bielack B, Bielack SS, Jürgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 20: 559-568.
45. Bielack SS, Kempf-Bielack B, Branscheid D et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive Cooperative Osteosarcoma Study Group patients. J Clin Oncol 2009; 27: 557-565.
46. Carrle D, Bielack SS. Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res 2009; 152: 165-184.
47. Langer T, Stöhr W, Paulides M et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr 2005; 217: 176-181.
48. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743.
49. Rossi R, Gödde A, Kleinebrand A et al. Unilateral nephrectomy and cisplatin as risk-factors for ifosfamide-induced nephrotoxicity. Analysis of 120 patients. J Clin Oncol 1994; 12: 159-165.
50. Aung L, Gurlick RG, Shi W et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer 2002; 95: 1728-1734.